XRay Vision: A Phase 3 Study of Xevinapant Plus Radiotherapy (RT) for High-risk, Cisplatin-ineligible Patients with Resected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN)

The current standard of care for patients (pts) with resected LA SCCHN who are at high-risk of disease recurrence and are cisplatin eligible is chemoradiotherapy (CRT; cisplatin  + RT). For pts who cannot receive cisplatin, treatment options are limited, and there is currently no treatment specifically recommended by international guidelines. Xevinapant, a first-in-class, small-molecule inhibitor of apoptosis protein inhibitor, has been shown to restore cancer cell sens itivity to apoptosis, thereby enhancing the effects of chemotherapy and RT.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: 107 Source Type: research